Trials / Completed
CompletedNCT01327547
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maraviroc | 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy |
| DRUG | Placebo | 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy |
Timeline
- Start date
- 2011-05-18
- Primary completion
- 2013-04-23
- Completion
- 2015-03-24
- First posted
- 2011-04-01
- Last updated
- 2017-12-06
- Results posted
- 2014-11-14
Locations
48 sites across 9 countries: United States, Czechia, France, Germany, Hungary, Poland, Puerto Rico, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01327547. Inclusion in this directory is not an endorsement.